STE Stock Analysis: STERIS | NYSE
Medical Devices | NYSE, USA | Market Cap: 22.589m USD | 12M Return: 1.6% | IE00BFY8C754 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 163M
EPS Trend: 98.7%
Qual. Beats: 1
Rev. Trend: 92.8%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
STERIS plc (NYSE: STE) is a global provider of infection prevention products and services, organized into three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Its offerings span cleaning chemistries, sterility assurance products, endoscope reprocessors and accessories, sterilizers, washers, surgical tables and lights, and instrument repair and maintenance services, as well as outsourced sterile processing for hospitals and contract sterilization, process validation, and equipment support for medical device and pharmaceutical manufacturers. The company is headquartered in Mentor, Ohio, and serves healthcare providers, medical device and pharmaceutical manufacturers, and biopharmaceutical facilities across the United States, Ireland, and other international markets. Founded in 1985 and listed on the NYSE in 1992, STERIS sits within the Health Care Equipment sub-industry and benefits from a business model that combines capital equipment sales with recurring service revenue from maintenance contracts and industrial-scale contract sterilization, a mission-critical step in the production of single-use medical devices.
- Hospital procedure volumes drive Healthcare consumables and services revenue
- Medical device sterilization demand lifts Applied Sterilization Technologies margins
- Biopharma capex recovery supports Life Sciences segment revenue growth
| Net Income: 805.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.79 > 1.0 |
| NWC/Revenue: 19.70% < 20% (prev 20.30%; Δ -0.61% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.29b > Net Income 805.1m |
| Net Debt (1.73b) to EBITDA (1.81b): 0.96 < 3 |
| Current Ratio: 5.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.9m) vs 12m ago -0.91% < -2% |
| Gross Margin: 44.43% > 18% (prev 44.13%; Δ 0.31% > 0.5%) |
| Asset Turnover: 59.99% > 50% (prev 53.54%; Δ 6.45% > 0%) |
| Interest Coverage Ratio: 18.80 > 6 (EBIT TTM 1.14b / Interest Expense TTM 60.6m) |
| A: 0.12 (Total Current Assets 1.43b - Total Current Liabilities 243.4m) / Total Assets 9.72b |
| B: 0.32 (Retained Earnings 3.15b / Total Assets 9.72b) |
| C: 0.11 (EBIT TTM 1.14b / Avg Total Assets 10.1b) |
| D: 2.92 (Book Value of Equity 7.22b / Total Liabilities 2.47b) |
| Altman-Z'' = 5.68 = AAA |
| DSRI: 0.99 (Receivables 1.01b/947.1m, Revenue 6.04b/5.57b) |
| GMI: 0.99 (GM 44.13% / 44.43%) |
| AQI: 1.04 (AQ_t 0.61 / AQ_t-1 0.59) |
| SGI: 1.08 (Revenue 6.04b / 5.57b) |
| TATA: -0.05 (NI 805.1m - CFO 1.29b) / TA 9.72b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of August 09, 2026, the stock is trading at USD 237.47 with a total of 633,977 shares traded. Over the past week, the price has changed by +3.97%, over one month by +10.25%, over three months by +11.45% and over the past year by +1.59%.
Current recommended Stop Loss: 220.40 (which is 7.2% or 2.5 ATR below the current price).
STERIS has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold STE.
- StrongBuy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 255.4 | 7.5% |
P/E Trailing = 29.1914
P/E Forward = 20.9205
P/S = 3.8054
P/B = 3.159
P/EG = 1.8831
Revenue TTM = 6.04b USD
EBIT TTM = 1.14b USD
EBITDA TTM = 1.81b USD
Long Term Debt = 1.81b USD (from longTermDebt, last fiscal year)
Short Term Debt = 243.4m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (corrected: LT Debt 1.81b + ST Debt 243.4m) + Leases 155.4m
Net Debt = 1.73b USD (calculated: Debt 2.21b - CCE 482.3m)
Enterprise Value = 24.3b USD (22.6b + Debt 2.21b - CCE 482.3m)
Interest Coverage Ratio = 18.80 (Ebit TTM 1.14b / Interest Expense TTM 60.6m)
EV/FCF = 26.27x (Enterprise Value 24.3b / FCF TTM 925.6m)
FCF Yield = 3.81% (FCF TTM 925.6m / Enterprise Value 24.3b)
FCF Margin = 15.33% (FCF TTM 925.6m / Revenue TTM 6.04b)
Net Margin = 13.33% (Net Income TTM 805.1m / Revenue TTM 6.04b)
Gross Margin = 44.43% ((Revenue TTM 6.04b - Cost of Revenue TTM 3.35b) / Revenue TTM)
Gross Margin QoQ = 45.84% (prev 43.89%)
Tobins Q-Ratio = 2.50 (Enterprise Value 24.3b / Total Assets 9.72b)
Interest Expense / Debt = 2.74% (Interest Expense 60.6m / Debt 2.21b)
Taxrate = 25.79% (280.8m / 1.09b)
NOPAT = 845.4m (EBIT 1.14b * (1 - 25.79%))
Current Ratio = 5.89 (Total Current Assets 1.43b / Total Current Liabilities 243.4m)
Debt / Equity = 0.31 (Debt 2.21b / totalStockholderEquity, last quarter 7.22b)
Debt / EBITDA = 0.96 (Net Debt 1.73b / EBITDA 1.81b)
Debt / FCF = 1.87 (Net Debt 1.73b / FCF TTM 925.6m)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.00% (Net Income 805.1m / Total Assets 9.72b)
RoE = 11.27% (Net Income TTM 805.1m / Total Stockholder Equity 7.15b)
RoCE = 12.72% (EBIT 1.14b / Capital Employed (Equity 7.15b + L.T.Debt 1.81b))
RoIC = 8.97% (NOPAT 845.4m / Invested Capital 9.42b)
WACC = 6.34% (E(22.6b)/V(24.8b) * Re(6.76%) + D(2.21b)/V(24.8b) * Rd(2.74%) * (1-Tc(0.26)))
Discount Rate = 6.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -80.33 | Cagr: -0.43%
[DCF] Terminal Value 75.68% ; FCFF base≈918.9m ; Y1≈936.9m ; Y5≈1.02b
[DCF] Fair Price = 145.0 (EV 15.9b - Net Debt 1.73b = Equity 14.1b / Shares 97.5m; r=8.35% [WACC [floored]]; 5y FCF grow 1.85% → 2.50% )
EPS Correlation: 98.72 | EPS CAGR: 8.02% | SUE: 0.90 | # QB: 1
Revenue Correlation: 92.79 | Revenue CAGR: 8.45% | SUE: -0.16 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.70 | Chg30d=+0.07% | Revisions=+12% | Analysts=8
EPS next Quarter (2026-12-31): EPS=2.82 | Chg30d=+0.11% | Revisions=+12% | Analysts=8
EPS current Year (2027-03-31): EPS=11.16 | Chg30d=+0.06% | Revisions=-25% | GrowthEPS=+9.8% | GrowthRev=+7.3%
EPS next Year (2028-03-31): EPS=12.21 | Chg30d=+0.27% | Revisions=-25% | GrowthEPS=+9.4% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +0% (up=6, down=6)